scholarly journals HBV and HCV infection among non-European Union immigrants in North-East Italy

1998 ◽  
Vol 121 (1) ◽  
pp. 179-183 ◽  
Author(s):  
M. CHIARAMONTE ◽  
A. PUPO ◽  
T. MENEGON ◽  
V. BALDO ◽  
R. MALATESTA ◽  
...  

The status of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among non-European Union (non-EU) immigrants in North-East Italy was evaluated. Among the 1683 individuals tested the prevalence of HBsAg was 8·9% (150 subjects) and of HBV antibodies (anti-HBc with/without anti-HBs) was 38·9% (654 subjects). The distribution of HBV serological markers showed significant differences according to region of origin; the highest prevalence of infection (76·9%) and carriage (16·1%) was found in immigrants from sub-Saharan Africa. Among the 933 individuals screened for HCV infection, prevalence of antibody was much lower (0·9%) than that observed in the Italian general population (3·2–12·6%). The large number of HBV carriers among immigrants could increase the number of new adult infections due to life-style habits or professional risks in the host population. In contrast, the risk of HCV spread from non-EU immigrants is very low.

2014 ◽  
Vol 35 (2) ◽  
pp. 409-416 ◽  
Author(s):  
Pierre Sellier ◽  
Sarah Maylin ◽  
Rishma Amarsy ◽  
Marie-Christine Mazeron ◽  
Lucile Larrouy ◽  
...  

2019 ◽  
Vol 113 (8) ◽  
pp. 437-445
Author(s):  
Anders Boyd ◽  
Menan Gerard Kouamé ◽  
Laura Houghtaling ◽  
Raoul Moh ◽  
Delphine Gabillard ◽  
...  

Abstract Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Côte d’Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as ‘infection’ (HBV DNA ≤10 000 copies/mL and normal alanine aminotransferase [ALT]) or ‘hepatitis’ (HBV DNA >10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19–31), 17 (40%) patients consistently had ‘infection’, 5 (12%) consistently had ‘hepatitis’ and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p<0.001), higher baseline ALT levels (p=0.02) and baseline hepatitis surface antigen >4.0 log10 IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation.


2019 ◽  
Vol 35 (3) ◽  
pp. 367-390 ◽  
Author(s):  
Jurgen Poesche

The objective of this article is to contribute to the development of a common narrative on coloniality in Sub-Saharan Africa and the Americas. Since scholars tend to focus on either Sub-Saharan Africa or the Americas, a gap between these important regions has emerged in the literature on coloniality. This article seeks to bridge this gap by providing a comparative perspective on coloniality, and this hopefully will enhance Indigenous African nations’ and Indigenous American nations’ understanding of what needs to be done to overcome coloniality. The article explores three key theses. First, in spite of the differences in the extant societal power structures in the postcolonial African states and the former settler colonial states in the Americas, this article argues that the continued dynamics of coloniality are similar in Sub-Saharan Africa and the Americas. The minority status of Indigenous American nations throughout the Americas renders addressing coloniality more challenging than in Sub-Saharan Africa where Indigenous African nations are in the majority although they generally do not have effective sovereignty. Second, the extant societal power structures associated with both coloniality and occidental modernity have weaponized occidental jurisprudence, natural science and social science to defend and proliferate the status quo assisted by state sovereignty. Addressing coloniality effectively therefore requires a renaissance of Indigenous African and Indigenous American cosmovisions unaffected by modernity. Third, addressing coloniality in Sub-Saharan Africa and the Americas requires the recognition of the comprehensive and supreme sovereignty of the Indigenous African nations in all of Sub-Saharan Africa, and Indigenous American nations in all of the Americas.


Blood ◽  
2003 ◽  
Vol 101 (6) ◽  
pp. 2419-2425 ◽  
Author(s):  
Jean-Pierre Allain ◽  
Daniel Candotti ◽  
Kate Soldan ◽  
Francis Sarkodie ◽  
Bruce Phelps ◽  
...  

The risk of hepatitis B virus (HBV) transmission by transfusion in sub-Saharan Africa is considered to be relatively low, and testing of blood donors is often not done or is done relatively poorly. To re-examine this attitude, we identified HBV chronically infected blood donors from a major hospital in Ghana with a range of hepatitis B surface antigen (HBsAg) assays. Test efficacy was estimated using HBV DNA as a gold standard, and the risk of HBV infection in blood recipients was estimated for different testing strategies. Particle agglutination, dipstick, and enzyme immunoassay (EIA) HBsAg screening detected 54%, 71%, and 97% of HBV infectious donors, respectively. The risk of HBV transmission to recipients less than 10 years old ranged between 1:11 and 1:326 with blood unscreened and screened by EIA, respectively. For older recipients, the risk decreased a further 4-fold because of the high frequency of natural exposure to HBV. A total of 98% of HBsAg-confirmed positive samples contained HBV DNA. HBV DNA load was less than 1 × 104 IU/mL in 75% of HBsAg-reactive samples, most of them anti-HBe reactive. Approximately 0.5% of HBsAg-negative but anti-HBc-positive samples contained HBV DNA. The use of sensitive HBsAg tests is critical to prevent transfusion transmission of HBV infection to young children in a population with a 15% prevalence of chronic HBV infection in blood donors. However, this will not have much effect on the prevalence of this infection unless other strategies to protect children from infection are also advanced in parallel.


2019 ◽  
Vol 4 (Suppl 3) ◽  
pp. A1-A1 ◽  
Author(s):  
Pauline Beattie ◽  
Moses Bockarie ◽  

The EDCTP community meets biennially to share research findings, plan new partnerships and collaborations, and discuss maximising impact from EDCTP-funded research. In 2018, the Ninth EDCTP Forum took place in Lisbon, Portugal, from 17–21 September 2018. The Lisbon meeting was the largest international conference focusing on clinical research on poverty-related infectious diseases in sub-Saharan Africa. It started with a strong commitment, from European and African EDCTP member countries, for a successor programme to EDCTP2 (2014–2024). It provided a platform for the presentation of project results and discussion of progress in clinical research and capacity strengthening in sub-Saharan Africa.The theme of the Ninth Forum was ‘Clinical research and sustainable development in sub-Saharan Africa: the impact of North-South partnerships’. This reflected not only the broader scope of a larger EDCTP research programme but also the growing awareness of the need for global cooperation to prepare for public health emergencies and strengthen health systems. The theme highlighted the impact of Europe-Africa partnerships supporting clinical research and the clinical research environment, towards achieving the sustainable development goals in sub-Saharan Africa.A central topic of the Forum was the discussion of the character and scope of an EDCTP successor programme, which should start in 2021 under the next European Framework Programme for Research and Innovation, Horizon Europe. On 17 September, a high-level meeting on this topic took place immediately before the opening of the Forum1. On 19 September, the plenary session continued this discussion through a panel of representatives of strategic partners. There was consensus on the added value of the programme for Europe and the countries in sub-Saharan Africa and political commitment to a successor programme. Poverty-related infectious diseases and a partnership approach will remain central to the programme. There was also a general awareness that all participating countries would need to engage more strongly with a successor programme, both in its governance and in their financial contributions to its objectives.The Forum hosted 550 participants from more than 50’countries. The programme consisted of keynote addresses by policy makers, research leaders, and prominent speakers from Europe and Africa in 5 plenary presentations. There were 9 symposia, 45 oral presentations in parallel sessions, and 74 electronic poster presentations. Abstracts of the plenary, oral and poster presentations are published in this supplement to BMJ Global Health.EDCTP is proud of its contribution to strengthening clinical research capacity in Africa, with more than 400 postgraduate students and 56 EDCTP fellows supported under the first EDCTP programme. The second programme developed a comprehensive fellowship scheme. More than 100 EDCTP fellows (former and current) participated in a one-day pre-conference to discuss the further development of our Alumni Network launched in 2017. The Forum also offered scholarships to many early and mid-career researchers from sub-Saharan Africa and Europe. With the support of the European Union, EDCTP member countries and sponsors, they were able to present results of their studies and meet colleagues from Africa and Europe.The Forum also provided the appropriate platform for recognising individual and team achievements through the four EDCTP 2018 Prizes. With the support of the European Union, EDCTP recognised outstanding individuals and research teams from Africa and Europe. In addition to their scientific excellence, the awardees made major contributions to the EDCTP objectives of clinical research capacity development in Africa and establishing research networks between North and South as well as within sub-Saharan Africa.Dr Pascoal Mocumbi Prize Professor Souleyman Mboup (Professor of Microbiology, University of Cheikh Anta Diop, Dakar; Head of the Bacteriology-Virology Laboratory of CHU Le Dantec, Dakar; and President of IRESSEF, Senegal) was recognised for his outstanding achievements in advancing health research and capacity development in Africa.Outstanding Research Team Prize The prize was awarded to the team of the CHAPAS (Children with HIV in Africa – Pharmacokinetics and acceptability of simple antiretroviral regimens) studies, led by Professor Diana Gibb (MRC Clinical Trials Unit, United Kingdom).Outstanding Female Scientist Prize The prize was awarded to Professor Gita Ramjee (Chief Specialist Scientist and Director of the HIV Prevention Research Unit of the South African Medical Research Council, Durban, South Africa) for her outstanding contributions to her field.Scientific Leadership Prize The prize was awarded to Professor Keertan Dheda (Head of the Centre for Lung Infection and Immunity and Head of the Division of Pulmonology at Groote Schuur Hospital and the University of Cape Town, South Africa) for his research contributions and leadership.Partnership is at the core of the EDCTP mission. In the year before the Forum, Nigeria and Ethiopia were welcomed as the newest member countries of the EDCTP Association, while Angola became an aspirant member. Partnership was also demonstrated by the many stakeholders who enriched the programme by organising scientific symposia, collaborative sessions and workshops. We thank our sponsors Novartis, Merck, the European Union, the Federal Ministry of Education and Research (Germany), the Institute of Health Carlos III (Spain), the National Alliance for Life Sciences and Health (France), the Medical Research Council (United Kingdom), the Swedish International Development Agency (Sweden), ClinaPharm (African CRO), the Deutsche Stiftung Weltbevölkerung (Germany), The Global Health Network (United Kingdom), PATH, and ScreenTB. We gratefully acknowledge the support of our partners and hosts of the Forum, the Portuguese Foundation for Science and Technology and the Calouste Gulbenkian Foundation.The tenth EDCTP Forum will take place in sub-Saharan Africa in 2020.


2017 ◽  
Vol 17 (S1) ◽  
Author(s):  
Patrick A. Coffie ◽  
◽  
Matthias Egger ◽  
Michael J. Vinikoor ◽  
Marcel Zannou ◽  
...  

Oryx ◽  
1991 ◽  
Vol 25 (3) ◽  
pp. 137-146 ◽  
Author(s):  
John H. Fanshawe ◽  
Lory H. Frame ◽  
Joshua R. Ginsberg

This paper presents a synopsis of the current status and distribution of the African wild dog Lycaon pictus, outlines reasons for its decline and discusses recommendations to halt or reverse this decline. A recent review of the status of the species provides evidence that it has disappeared or is in decline throughout its range (sub-Saharan Africa). Relict populations with little or no chance of long-term survival are found in several countries including Algeria and Senegal. Countries believed to contain potentially viable populations are, from north to south, Kenya, Tanzania, Zambia, Zimbabwe, Botswana, and South Africa (only the Kruger National Park).


Sign in / Sign up

Export Citation Format

Share Document